Compass Pathways Akcia

Compass Pathways EPS

Zisk na akciu (EPS) spoločnosti Compass Pathways (CMPS) k 4. 8. 2026 je -3,07 USD. V predchádzajúcom roku Zisk na akciu (EPS) bolo -2,27 USD — zmena o 35,69 % (nižšie).

EPS

-3,07USD

YoY

35,69%

Naposledy aktualizované:

Zisk na akciu (EPS) spoločnosti Compass Pathways je 2026 -3,07 USD. Zisk na akciu (EPS) spoločnosti Compass Pathways bolo 2025 -2,27 USD. Klesá teda o 35,69% nižšie oproti predchádzajúcemu roku.
Access this data via the Eulerpool API

Compass Pathways Analýza akcií

Čo robí Compass Pathways? Compass Pathways PLC is a leading company specializing in the development of groundbreaking therapies for the treatment of mental illnesses. The company was founded in 2016 and is headquartered in London. Its goal is to revolutionize the treatment of depression and other mental illnesses. The business model of Compass Pathways is based on researching psychedelics as a potential treatment for patients suffering from severe depression and anxiety disorders. The company uses innovative approaches to precisely study the effects of psychedelics on the human brain and develop new therapy concepts and products from that. An important area of Compass Pathways is clinical research. The company collaborates closely with leading research institutions to understand the impacts of psychedelics on the human brain. The research results are then used to develop innovative methods for therapeutic use of psychedelics. Another important area of Compass Pathways is the development of therapeutic products. The company has developed a patented process for producing psilocybin, a substance found in hallucinogenic mushrooms. This process achieves a very high purity of the substance, enabling precise dosing and better control of its effects. The flagship product of Compass Pathways is COMP360, a medication based on psilocybin that is being developed for the treatment of depression. The medication is currently in clinical Phase 2 trials, showing promising results. If COMP360 receives approval, it has the potential to drastically change the way we treat depression. Compass Pathways is also active in other areas. The company conducts a range of research projects related to various psychedelic substances, including LSD and other hallucinogens. Another important area of Compass Pathways is training therapists and other professionals in the use of psychedelic substances. The company offers relevant courses to promote understanding of the therapeutic use of psychedelics and enable their safe and effective application for patient treatment. Overall, Compass Pathways is a company focused on the development of groundbreaking therapies for mental illnesses. Through combining cutting-edge research, innovative products, and professional education, the company has the potential to revolutionize the way we treat mental illnesses. Compass Pathways je jednou z najobľúbenejších spoločností na Eulerpool.

Často kladené otázky o akcii Compass Pathways

Zisk na akciu (EPS) spoločnosti Compass Pathways je -3,07 USD v roku 2026.

Zisk na akciu (EPS) spoločnosti Compass Pathways sa zmenil z -2,27 USD na -3,07 USD, čo predstavuje zmenu 35,69 %. Hodnota je nižšie ako v predchádzajúcom roku.

Na Eulerpool nájdete kompletnú historickú evolúciu Compass Pathways Zisk na akciu (EPS) od roku 2006 – s ročnými hodnotami, grafmi a detailnou analýzou.

Zisk na akciu meria podiel na zisku spoločnosti, ktorý připadá na každú vydanú akciu. Je to kľúčová metrika na posúdenie ziskovosti spoločnosti na základe akcie.

EPS = Čistý zisk / Vydané akcie

Access this data via the Eulerpool API

Výkaz ziskov a strát — Compass Pathways

Všetky kľúčové ukazovatele — Compass Pathways